GLPwatch
Soliqua for MASH (metabolic dysfunction-associated steatohepatitis)
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSoliqua (lixisenatide) is not FDA-approved for MASH, and any use for this condition is off-label or investigational. A systematic review with individual patient data meta-analysis of randomized controlled trials in type 2 diabetes patients found that lixisenatide may affect elevated liver transaminases, but this does not establish efficacy for MASH.
AI summary of the sources below.
| Drug | Soliqua (lixisenatide) |
|---|---|
| Condition | MASH (metabolic dysfunction-associated steatohepatitis) |
| Approval status | Investigational / off-label |
| Research papers | 1 |
Soliqua is not FDA-approved for mash (metabolic dysfunction-associated steatohepatitis); the research below reflects investigational or off-label study only.